China's rise as the world's largest pharmaceutical biotechnology investmentTime：2017-05-03Frome：Moxi
According to the United States, "the Wall Street journal" reported on April 11th, China is emerging as a major producer of biotech drugs, which caused some of the world's Big Pharma's attention over the past two years, Eli Lilly and Merck pharmaceutical company signed a multimillion dollar agreement with China company, will Chinese biotechnology drug development overseas.
A new cancer drug approved by Eli Lilly is developed by a start-up company in Shanghai, six years old, from Chinese hamster ovary cells. Lilly plans to test the new drug in American patients.
Rival Merck Co plans to test another cancer drug in the United States this year, which is being developed by another start-up near Hongkong.
Reported that these cases are not isolated cases. China, which has long been the world's leading supplier of cheap drugs and generic drugs, is now emerging as a major producer of important new drugs, such as biotech drugs. According to the National Institutes of health, China is now second only to the United States in terms of the number of clinical trials in the field of biological treatment.
This situation has attracted the attention of some large pharmaceutical companies around the world.
Merck Co sent executives to search for a large number of Chinese start-ups, and in 2015 in Shanghai set up a dedicated innovation center. Johnson also set up a similar center in Shanghai in 2014, in order to grasp the trend of China's scientific and technological breakthroughs. Over the past two years, Eli Lilly, Merck, Tesaro Inc. (TSRO) and Incyte Co. (INCY) have signed a multimillion dollar agreement with Chinese companies, China will develop biotechnology drugs sold overseas.
Will China change overnight? Sanofi emerging market leader Schall Mey that will not. But he also said that once the direction is determined, the situation is clearly changing, he pointed out that China is to improve the quality of products and resources.
There are differences between biological drugs and chemical drugs, and has revolutionized the treatment of diseases such as cancer and diabetes. Bio medicine is developed by Western pharmaceutical companies in their own laboratories in the past few decades, lucrative. Frost, a consulting firm, says eight of the world's top ten best-selling drugs are biological drugs, according to the company, which is based on the. But the industry group, the American Association for drug research and the Pharmaceutical Manufacturers Association, said that the cost of developing more than $1 billion for each kind of biological drug, it may take more than ten years to market.
Global pharmaceutical makers are increasingly turning to other regions to seek new breakthroughs in the face of the pressure of a series of costly failures and the continued decline in patent protection.
Reported that, as part of promoting local pharmaceutical industry reform, the government has Chinese to domestic drug production enterprises invest a lot of money, and the incentive measures: the establishment of China attract scientists working overseas home projects, poured billions of dollars into focus at the beginning of biotechnology technology park enterprises, biotechnology research and development of new drug approval test achieved speed.
Reported that the most China start-ups by copying or improvement of existing initial biotech drugs, but some enterprises are entering higher risk business, research has not yet been human trials of biological agents.
Headquartered in biopharmaceutical startups XinDa near Shanghai (Suzhou) Co. Ltd. in 2015 reached China pharmaceutical enterprises by far the biggest deal, then Eli Lilly company to pay $56 million for the joint development of three kinds of cancer drugs, including two kinds of drugs are XinDa bio pharmaceutical research. If the above drug standards, XinDa biopharmaceutical is expected to earn more than $1 billion 400 million in the next ten years.
Reported that, in a small laboratory bio pharmaceutical XinDa located in the Suzhou Industrial Park, dozens of known as the bioreactor cylindrical glass vessel containing China body made from hamster cells, the rodents are commonly used in global pharmaceutical research. The drug is used to block a gene that interferes with the body's ability to fight cancer, according to lilly.
XinDa biopharmaceutical in China has begun testing the drug for patients, while Eli Lilly is preparing to apply for its own clinical trials in the United states. Eli Lilly said that once the drug is approved, plans to sell outside the global market in China, in China, the company holds a joint marketing and XinDa biopharmaceutical.
According to ChinaBio data, China biotech boom has attracted venture capital participation, promote the China Life Sciences investment reached a record $5 billion 300 million last year, compared with five years ago increased by nearly 10 times.
Lilly founded a venture capital fund to invest in Asia in 2008, and since then the fund has invested almost $five hundred million in China's biotech start-ups.
The fund partner said that 10 years ago, China is not even in the field of biotechnology concern, but now has become a force can not be ignored.